sugemalimab   Click here for help

GtoPdb Ligand ID: 12342

Synonyms: Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
Approved drug
sugemalimab is an approved drug (China (2021), EMA (2021))
Compound class: Antibody
Comment: Sugemalimab is a fully human, high-affinity anti-programmed death ligand 1 (PD-L1) IgG4 monoclonal antibody. It is a checkpoint inhibitor class immuno therapeutic. In vitro, it competitively blocks the binding of human PD-L1 to PD-1 and CD80, and it induces T lymphocyte proliferation and enhances antitumour immunity [2].
Classification Click here for help
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (China (2021), EMA (2021))
Approved drug? Yes. China (2021)
International Nonproprietary Names Click here for help
INN number INN
11330 sugemalimab
Synonyms Click here for help
Cejemly® (China) | CS-1001 | CS1001 | WBP-3155 | WBP3155
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1031
Other databases
GtoPdb PubChem SID 479821133
Search PubMed clinical trials sugemalimab
Search PubMed titles sugemalimab
Search PubMed titles/abstracts sugemalimab